TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12612227

Group type: EXPERIMENTAL
Intervention: Scheduling an appointment at the time of an ED visit
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group (no scheduling assistance)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 278
Study: 10848879

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (6 U/m2/day) with low dose ethinyl oestradiol, administered either once daily (OD) or twice daily (BID)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (6 U/m2/day) with low dose ethinyl oestradiol
Number of subjects: 19
Study: 9019175

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Suxamethonium 1 mg/kg
Number of subjects: 40
Study: 1584737

Group type: EXPERIMENTAL
Intervention: Hyposensitization
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 4064277

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Volume loading
Number of subjects: 13
Study: 29460811

Group type: EXPERIMENTAL
Intervention: Viscosity-regulating pectin solution (VREF group, n = 15)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional enteral nutrition administration (Control group, n = 12)
Number of subjects: 34
Study: 26764413

Group type: EXPERIMENTAL
Intervention: ivabradine 2×7.5 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 25018120

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) 0.5 mL intramuscularly (containing 40, 8, and 32 D antigen units for serotypes 1, 2, and 3)
Number of subjects: 450

Group type: COMPARATOR
Intervention: No vaccine (control group)
Number of subjects: 450
Study: 22199171

Group type: EXPERIMENTAL
Intervention: cerebellar continuous theta burst stimulation (cTBS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects (no stimulation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: cerebellar cTBS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control experiments
Number of subjects: 30
Study: 19446951

Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate 800 mg/d
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oxybutynin 15 mg/d
Number of subjects: 135
Study: 17661792

Group type: EXPERIMENTAL
Intervention: Selective serotonin re-uptake inhibitor (SSRI) treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Patients with acute stroke and PC
Number of subjects: 8
Study: 15640476

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg Zn daily)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 12195349

Group type: EXPERIMENTAL
Intervention: Saquinavir in combination with either ritonavir or nelfinavir, plus delavirdine, adefovir, or both; duration: 48 weeks
Number of subjects: 105
Study: 11551136

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment after neoadjuvant chemotherapy
Number of subjects: 0
Study: 9923574

Group type: EXPERIMENTAL
Intervention: Tacrine treatment with serum concentrations above 7 ng/ml
Number of subjects: 106

Group type: COMPARATOR
Intervention: Tacrine treatment with serum concentrations below 7 ng/ml
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Tacrine treatment with serum concentrations above 5 ng/ml
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Tacrine treatment with serum concentrations above 9 ng/ml
Number of subjects: 106
Study: 8091959

Group type: EXPERIMENTAL
Intervention: Symptoms of craniomandibular disorders (CMD)
Number of subjects: 364
Study: 3073322

Group type: EXPERIMENTAL
Intervention: 4 mg morphine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 8 mg morphine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.5 mg new analgesic
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 mg new analgesic
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29956471

Group type: EXPERIMENTAL
Intervention: octenidine-based hydrogel wound dressing
Number of subjects: 45

Group type: COMPARATOR
Intervention: standard postoperative wound dressing
Number of subjects: 45
Study: 28667705

Group type: EXPERIMENTAL
Intervention: More mental effort on a writing task
Number of subjects: 97

Group type: COMPARATOR
Intervention: Less mental effort on a writing task
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Emotional images
Number of subjects: 97

Group type: COMPARATOR
Intervention: Neutral images
Number of subjects: 97
Study: 26444692

Group type: EXPERIMENTAL
Intervention: Buffered Crystalloid
Number of subjects: 2278

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 2278
Study: 22595934

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost ophthalmic solution
Number of subjects: 184

Group type: COMPARATOR
Intervention: Xalatan
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 184
Study: 21203877

Group type: EXPERIMENTAL
Intervention: 90° rotation technique
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard technique (control)
Number of subjects: 126
Study: 18461846

Group type: EXPERIMENTAL
Intervention: Standard individual test-setting
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Triadic test-setting with another child observing
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Individual test-setting within the noisy kindergarten group
Number of subjects: 250

Group type: COMPARATOR
Intervention: Silent standard setting
Number of subjects: 250

Group type: COMPARATOR
Intervention: Noisy setting with children playing loudly outside
Number of subjects: 250

Group type: COMPARATOR
Intervention: Noisy setting with children singing loudly outside
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Test time and social setting variations (after arrival, after joint breakfast, before and after joint lunch)
Number of subjects: 250
Study: 16216827

Group type: EXPERIMENTAL
Intervention: ghrelin 40 mug administered intravenously over 30 minutes
Number of subjects: 9

Group type: COMPARATOR
Intervention: saline administered intravenously over 30 minutes
Number of subjects: 9
Study: 12665160

Group type: EXPERIMENTAL
Intervention: Grippostad-C (acetaminophen, caffeine, chlorpheniramine, ascorbic acid)
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Acetaminophen, caffeine, ascorbic acid (reference 2)
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine and ascorbic acid (reference 1)
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Ascorbic acid (control)
Number of subjects: 1167
Study: 11097610

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for RNFL measurements in normal eyes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for RNFL measurements in glaucoma eyes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Statistical model using three scans per patient for normal eyes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Statistical model using three scans per patient for glaucoma eyes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Variance analysis for RNFL measurements
Number of subjects: 20
Study: 9461937

Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg rectally followed by 20 mg daily for 7 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Piroxicam 40 mg rectally followed by 20 mg daily for 7 days
Number of subjects: 58
Study: 1356851

Group type: EXPERIMENTAL
Intervention: Valethamate bromide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 120
Study: 30199421

Group type: EXPERIMENTAL
Intervention: rhBMP‐2/HA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bovine bone
Number of subjects: 20
Study: 28546268

Group type: EXPERIMENTAL
Intervention: Home-based maintenance tele-rehabilitation
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Hospital-based outpatient maintenance rehabilitation
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study: 27101675

Group type: EXPERIMENTAL
Intervention: CPAP combined with modified oral appliance (MOA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 120
Study: 23746205

Group type: EXPERIMENTAL
Intervention: Dried purple carrot (118.5 mg/day of anthocyanins and 259.2 mg/day of phenolic acids for 4 weeks)
Number of subjects: 16
Study: 20305399

Group type: EXPERIMENTAL
Intervention: Astaxanthine (0.3 microM, 1 microM, 3 microM, 10 microM, 30 microM, and 100 microM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Astaxanthine (subclinical <1 microM, therapeutic 3 microM to 30 microM, supratherapeutic 100 microM)
Number of subjects: 20
Study: 19675107

Group type: EXPERIMENTAL
Intervention: Successful weight-loss maintainers (SWLs)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Obese controls
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal-weight (NW) controls
Number of subjects: 51
Study: 16737761

Group type: EXPERIMENTAL
Intervention: Glutamate infusion during 1h immediately after skin closure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline infusion during 1h immediately after skin closure
Number of subjects: 20
Study: 15381513

Group type: EXPERIMENTAL
Intervention: Brief intervention groups (two slightly different interventions)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Original study groups (intervention groups)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Pseudo-control group
Number of subjects: 338
Study: 11380487

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9640622

Group type: EXPERIMENTAL
Intervention: Dilazep
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8111140

Group type: EXPERIMENTAL
Intervention: New enterotropic peptide-based formula (NEF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard enteral formula (SEF)
Number of subjects: 80
Study: 3317180

Group type: EXPERIMENTAL
Intervention: 100 mg/kg of epsilon‐aminocaproic acid (EACA), orally every 4 hours for 5 days (maximum 30 g/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: EACA
Number of subjects: 49
Study: 29579763

Group type: EXPERIMENTAL
Intervention: Individualised homeopathic medicine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27802493

Group type: EXPERIMENTAL
Intervention: Ultrasonography invitation for screening
Number of subjects: 19249

Group type: COMPARATOR
Intervention: Control group without invitation
Number of subjects: 19249
Study: 24550153

Group type: EXPERIMENTAL
Intervention: Web-based PA intervention based on MI with an avatar
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Content-identical intervention without an avatar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 0
Study: 23072845

Group type: EXPERIMENTAL
Intervention: Homidium chloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diminazene aceturate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infected positive animals
Number of subjects: 0
Study: 20145446

Group type: EXPERIMENTAL
Intervention: Self-management interventions
Number of subjects: 23

Group type: COMPARATOR
Intervention: Educational interventions
Number of subjects: 23
Study: 18190370

Group type: EXPERIMENTAL
Intervention: Decision aid (24-page booklet)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 330
Study: 16020212

Group type: EXPERIMENTAL
Intervention: ALA-IPL treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: IPL treatment
Number of subjects: 7
Study: 12942480

Group type: EXPERIMENTAL
Intervention: Reconstructed ST-segment deviations (STdev) using mathematical formulas based on available leads on the 12-lead ECG.
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Reconstructed ST-segment resolution (STR) calculated from original data and from reconstructed STdev.
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Aggregate ST-segment resolution (STR) as an endpoint in trials.
Number of subjects: 1121
Study: 10540045

Group type: EXPERIMENTAL
Intervention: OBTM (Omeprazole 20 mg b.d., Bismuth 120 mg q.d.s., Tetracycline 500 mg q.d.s., Metronidazole 250 mg q.d.s.)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RbcTM (Ranitidine bismuth citrate 400 mg b.d., Tetracycline 500 mg q.d.s., Metronidazole 250 mg q.d.s.)
Number of subjects: 60
Study: 8905425

Group type: EXPERIMENTAL
Intervention: Intravenous octreotide (100 micrograms three times daily for 10 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no octreotide treatment)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intravenous octreotide
Number of subjects: 39
Study: 1804603

Group type: EXPERIMENTAL
Intervention: Low dose Aspirin (50 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6136132

Group type: EXPERIMENTAL
Intervention: H1 + H2-antagonists (Chlorpheniramine 4 X 4 mg/d and Cimetidine 4 X 400 mg/d for 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: H1-antagonist alone (Chlorpheniramine 4 X 4 mg/d for 4 weeks)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: H1 + H2-antagonists (Chlorpheniramine and Cimetidine for 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: H1-antagonist (Chlorpheniramine)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: H1 + H2-antagonists
Number of subjects: 15
Study: 30977467

Group type: EXPERIMENTAL
Intervention: Routine viral load (VL) monitoring
Number of subjects: 1973

Group type: COMPARATOR
Intervention: Discretionary viral load (VL) monitoring
Number of subjects: 1973
Study: 29582920

Group type: EXPERIMENTAL
Intervention: Training Continued (TC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Training Stopped (TS)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Subjective physical performance
Number of subjects: 28
Study: 26072396

Group type: EXPERIMENTAL
Intervention: Pretreatment screening for TPMT variants with dose reduction (50% for heterozygous carriers, 0%-10% for homozygous carriers)
Number of subjects: 783

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 783

Group type: COMPARATOR
Intervention: Both intervention and control groups
Number of subjects: 783
Study: 23718725

Group type: EXPERIMENTAL
Intervention: Artefan® (test)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Coartem® (reference)
Number of subjects: 18
Study: 20800445

Group type: EXPERIMENTAL
Intervention: Prospective screening for eligibility over 8 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Retrospective chart review
Number of subjects: 74
Study: 19550356

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: ABPM
Number of subjects: 157
Study: 17580509

Group type: EXPERIMENTAL
Intervention: Formaldehyde fixation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thymol storage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Freshly extracted teeth
Number of subjects: 0
Study: 12872102

Group type: EXPERIMENTAL
Intervention: Variable stiffness enteroscopy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional enteroscopy with overtube
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional enteroscopy without overtube
Number of subjects: 67
Study: 10861154

Group type: EXPERIMENTAL
Intervention: Posterior lumbar plexus block with 0.4 ml/kg bupivacaine, 0.5%, with epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia without lumbar plexus block (control group)
Number of subjects: 60
Study: 9351691

Group type: EXPERIMENTAL
Intervention: Cosmed K4 system
Number of subjects: 7
Study: 8477964

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (13 to 15 mg/kg/day)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 3757764

Group type: EXPERIMENTAL
Intervention: lipo‐PGE1 (5 micrograms/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PGE1CD (40 micrograms/day)
Number of subjects: 20
Study: 31931848

Group type: EXPERIMENTAL
Intervention: Oral azithromycin 10 mg/kg once daily for 3 days
Number of subjects: 11500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11500
Study: 30148871

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Mean albuminuria at 38 months
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Time-averaged albuminuria cut-off of 900 mg/day
Number of subjects: 165
Study: 28290800

Group type: EXPERIMENTAL
Intervention: Valsartan/HCT (Val/HCT) - group I
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quinapril/HCT (Quin/HCT) - group II
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Night-time DBP variability in group I
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Magnitude and speed of morning DBP surge in group I
Number of subjects: 50
Study: 24131075

Group type: EXPERIMENTAL
Intervention: CP 3 g (Group B)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CP 3 g and vitamin C 500 mg (Group C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No supplement (Group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vitamin C 500 mg (Group D)
Number of subjects: 32
Study: 22564464

Group type: EXPERIMENTAL
Intervention: Inhalant users
Number of subjects: 697

Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 697
Study: 19717481

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5993

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5993
Study: 18407003

Group type: EXPERIMENTAL
Intervention: Web-based smoking-cessation program plus nicotine patch
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Cumulative assignment of tailoring depth factors
Number of subjects: 1866
Study: 15839181

Group type: EXPERIMENTAL
Intervention: Achieved BP goal of less than 130/85 mm Hg
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Achieved BP goal of less than 130/80 mm Hg
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Prevalence of dyslipidemia
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Prevalence of overweight, obesity, or morbid obesity
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Prevalence of tobacco use
Number of subjects: 977
Study: 12428224

Group type: EXPERIMENTAL
Intervention: Oral pulse prednisolone, methotrexate, plus sulfasalazine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sulfasalazine alone
Number of subjects: 110
Study: 10898263

Group type: EXPERIMENTAL
Intervention: Overstride (−8% PSF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Understride (+8% PSF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal stride frequency
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Second downhill run (all groups)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 18
Study: 8893636

Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT)
Number of subjects: 13
Study: 1924640

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam four times daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine every morning
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam four times daily and 60 mg fluoxetine every morning
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo four times daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 80
Study: 7043341

Group type: EXPERIMENTAL
Intervention: PGE2 gel (2 ml containing 0.5 mg PGE2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo gel (gel without PGE2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PGE2 gel (0.5 mg) in subsequent open study
Number of subjects: 50
Study: 31849306

Group type: EXPERIMENTAL
Intervention: Group I (phone calls)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group II (text messages)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group III (control, standard advice at discharge)
Number of subjects: 120
Study: 29229898

Group type: EXPERIMENTAL
Intervention: Hepabulin (10,000 units) intravenously injected intraoperatively, daily for 1 week, weekly for 1 month, and then once per month
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Hepabulin (10,000 units)
Number of subjects: 87
Study: 25440110

Group type: EXPERIMENTAL
Intervention: Infusions prepared from 2 g of C citratus leaf powder once daily for 30 days
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Infusions prepared from 4 g of C citratus leaf powder once daily for 30 days
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Infusions prepared from 8 g of C citratus leaf powder once daily for 30 days
Number of subjects: 105
Study: 25169962

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 6
Study: 22971904

Group type: EXPERIMENTAL
Intervention: Passive walking-like leg movement (PWM) for 25 minutes at 1 Hz
Number of subjects: 13

Group type: COMPARATOR
Intervention: Quiet standing (QS) for 25 minutes
Number of subjects: 13
Study: 21060071

Group type: EXPERIMENTAL
Intervention: Omega-3-acid ethyl esters-90 (1 g/d for 1 year)
Number of subjects: 3851

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 3851
Study: 17714578

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16416000

Group type: EXPERIMENTAL
Intervention: Bicyclo tablets
Number of subjects: 148

Group type: COMPARATOR
Intervention: Hugan tablets
Number of subjects: 148